Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity

NCT: NCT07158177 · RECRUITING

NCT IDNCT07158177
StatusRECRUITING
Start Date2025-10-01
Completion2026-10-15

Brief Summary

Retrospective, comparative, interventional, randomized, single-center study, contralateral (the patient's 2 eyes will be implanted: 1 CPO and the other APO) Patients presenting for cataract surgery with a request for presbyopia correction and managed as part of routine clinical practice. The main aim of the study is to demonstrate that contrast sensitivity is better with the Clareon PanOptix (CPO) intraocular lens (IOL) compared with the AcrySof PanOptix (APO) IOL 3 months after implantation.

Frequently Asked Questions

What is Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity?

Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity is a clinical trial registered under NCT07158177. Current status: RECRUITING.

What is the status of NCT07158177?

The current status of NCT07158177 (Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity) is: RECRUITING.

When did Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity start?

Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity started on 2025-10-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑